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Aims. Migration of CD4-positive lymphocytes into the vessel wall is a critical step in atherogenesis. Recent data suggest
that ivabradine, a selective I(f)-channel blocker, reduces atherosclerotic plaque formation in apolipoprotein E-deﬁcient mice,
hitherto nothing is known about the mechanism by which ivabradine modulates plaque formation. Therefore, the present study
investigatedwhetherivabradineregulateschemokine-inducedmigrationoflymphocytes.Methodsandresults.StimulationofCD4-
positive lymphocytes with SDF-1 leads to a 2.0 ± 0.1 fold increase in cell migration (P<. 01; n = 7). Pretreatment of cells
with ivabradine reduces this eﬀect to a maximal 1.2 ± 0.1 fold induction at 0.1μmol/L ivabradine (P<. 01 compared to SDF-1-
treated cells, n = 7). The eﬀect of ivabradine on CD4-positive lymphocyte migration was mediated through an early inhibition of
chemokine-induced PI-3 kinase activity as determined by PI-3 kinase activity assays. Downstream, ivabradine inhibits activation
of the small GTPase Rac and phosphorylation of the Myosin Light Chain (MLC). Moreover, ivabradine treatment reduces f-actin
formation as well as ICAM3 translocation to the uropod of the cell, thus interfering with two important steps in T cell migration.
Conclusion. Ivabradine inhibits chemokine-induced migration of CD4-positive lymphocytes. Given the crucial importance of
chemokine-induced T-cell migration in early atherogenesis, ivabradine may be a promising tool to modulate this eﬀect.
1.Introduction
Atherogenesis is an inﬂammatory process in the vessel wall
involving inﬂammatory cells like monocytes, macrophages,
and CD4-positive lymphocytes [1, 2]. In early atherogenesis,
CD4-positive lymphocytes are attracted by chemotactic
proteins such as RANTES and SDF-1 and enter the vessel
wall as na¨ ıve TH0 cells. In the subendothelium, these cells
then encounter antigens like oxidized LDL and diﬀerentiate
into TH1 cells, subsequently releasing proinﬂammatory
mediators like TNF-α and Interferon-γ (IFNγ). These
cytokines then govern the inﬂammatory response in the
vessel wall by activating other cells such as endothelial
cells, macrophages, and vascular smooth muscle cells, thus
promotingtheinﬂammatoryprocessinatherogenesis.More-
over, experimental studies have shown that a reduction
in CD4-positive lymphocyte recruitment hampers lesion
development and plaque formation [3,4]. Still, most of these
studies targeted the eﬀect of T-cell-speciﬁc chemokines, but
hitherto little is known about modulatory eﬀects on CD4-
positive lymphocyte migration.
Epidemiological studies have shown that elevated heart
rate represents a risk factor for cardiovascular morbidity
both in primary prevention and in patients with hyperten-
sion, coronary artery disease, and myocardial infarction [5–
8]. Increased heart rate and reduced heart rate variability
have been shown to be associated with coronary plaque
rupture and subclinical inﬂammation in healthy middle-
aged and elderly subjects [9, 10].
Selective heart rate (HR) reduction by I(f)-channel
inhibition is a recently developed pharmacological principle
in cardiovascular therapy. Among these newly identiﬁed HR-
lowering drugs, only ivabradine has now become approved
for clinical use. I(f)-channel inhibition mainly reduces
HR, thereby improving myocardial oxygen supply, energy




























































































































































Figure 1: Ivabradine reduces SDF-1 and RANTES-induced CD4-positive lymphocyte migration. (a) Human CD4-positive cells were
pretreated with ivabradine for 15 minutes at concentrations indicated before migration experiments using SDF-1 (100ng/mL) were
performed in a modiﬁed Boyden chamber. Data are expressed as fold induction compared to SDF-1-stimulated cells. Bars represent mean ±
SD (n = 7); P<. 01 compared to chemokine-stimulated cells. (b) Human CD4-positive lymphocytes were pretreated with ivabradine for 15
minutes at concentrations indicated before migration experiments using RANTES (100pg/ml) were performed. Data are expressed as fold












































with ivabradine in diﬀerent concentrations for 15 minutes before cells were stimulated with SDF-1 (100ng/mL). After 5 minutes, PI 3-kinase
activityassaywasperformed.Speciﬁcdotsarelabelledwithanarrow(PIP).Threeindependentexperimentsshowedsimilarresults.(b)SDF-
1 leads to phosphorylation of AKT. Isolated CD4-positive lymphocytes were pretreated with ivabradine in diﬀerent concentrations indicated
beforestimulationwith100ng/mLSDF-1for10min.Totallysateswereanalyzedbyimmunoblottingemployingantibodiesagainstphospho-
AKT. Equal loading of intact protein was conﬁrmed by staining for GAPDH. Densitometric analysis were performed of 3 independent
experiments. Data are expressed as p-AKT normalized to GAPDH. Bars represent mean ± SD. ∗P<. 01 compared with SDF-1-stimulated
cells; n = 3.
and revealed a good safety proﬁle in the investigated study
populations.
Recent data have shown that treatment with ivabradine
reduces oxidative stress, improves endothelial function, and
prevents atherosclerosis in apolipoprotein E-deﬁcient mice.
In this study, ivabradine treatment leads to a reduction
in oxidative stress and to a potent downregulation of
MCP-1 expression in atherosclerotic plaques, causing less
inﬂammation and decreased lesion size [11].
Nothingisknownaboutthedirecteﬀectofivabradineon
chemokine-induced migration.
Therefore, the current study examined the eﬀect of
ivabradine on CD4-positive lymphocyte migration and on
intracellular signaling molecules involved.
2. Methods
2.1. Cell Culture. Human CD4-positive lymphocytes were
isolated from freshly drawn blood of healthy volunteers
by Ficoll-Histopaque (Sigma-Aldrich, Germany) gradient
centrifugation to obtain mononuclear cells (PBMCs) and































































































Figure 3: Ivabradine inhibits SDF-1-induced activation of Rac1 and reduces phosphorylation of MLC. (a) Human CD4-positive cells were
pretreatedwithivabradine(0.01,0.05,and0.1μmol/L)for15minutesbeforecellswerestimulatedwithSDF-1(100ng/mL).After3minutes,
GTPase activity assay was performed (aﬃnity precipitation with GST-PAK). Densitometric analysis of 5 independent experiments. Bars
represent mean ± SD. ∗P<. 01 compared with SDF-1-stimulated cells. (b) SDF-1 leads to phosphorylation of MLC. Isolated CD4-positive
lymphocyteswerepretreatedwithivabradineindiﬀerentconcentrationsindicatedbeforestimulationwith100ng/mLSDF-1for5min.Total
lysates were analyzed by immunoblotting employing antibodies against phospho-MLC. Equal loading of intact protein was conﬁrmed by
staining for GAPDH. Densitometric analyses were performed of 5 independent experiments. Data are expressed as p-MLC normalized to
GAPDH. Bars represent mean ± SD. ∗P<. 01 compared with SDF-1-stimulated cells; n = 5.
magnetic bead separation (Miltenyi Biotec, Germany) as
described by the manufacturer’s protocol. The investigation
conforms with the principles outlined in the Declaration
of Helsinki and was granted by the university ethics review
board. The purity of CD4-positive T cells was >97% as
determined by ﬂow cytometry.
2.2. In Vitro Cell Migration Assay. After isolation, CD4-
p o s i t i v ec e l l sw e r ec u l t u r e di ns e r u m - f r e em e d i af o r1 6 h .
T-cell chemotaxis was assayed under serum-free conditions
in a 48-well microchemotaxis chamber (Neuroprobe, USA).
Wells in the upper and lower chamber were separated by
a polyvinylpyrrolidone-free polycarbonate membrane (pore
size 5μm; Costar, Cambridge, MA). CD4-positive cells at
a density of 5 × 105/ml were pretreated for 15min with
ivabradine before 3 hours of incubation with SDF-1 or
RANTES (Sigma-Aldrich, Germany). Migrated cells on the
bottom face of the ﬁlter were stained and counted under
the light microscope. Cells were counted in 5 random high-
power ﬁelds per well (in control about 200–300 cells and in
SDF-1 or RANTES-induced conditions about 600–700 cells
per 5 random power ﬁelds per well).
2.3. Western Blot Analysis. CD4-positive lymphocytes were
left untreated or incubated at 37◦C with 100ng/mL RANTES
(Sigma) or with 100ng/mL SDF-1α (Upstate, Lake Placid,
NY, USA) for times indicated. Cells were lysed in lysis
buﬀer (50mmol/L Hepes pH 7.4, 150mmol/L NaCl, 1%
(w/v) NP40, 1% (w/v) glycerol, 1mmol/L MgCl2, 1mmol/L
MnCl2, 10mmol/L NaF, 1mM Na3VO4,1 0μg/μl aprotinin,
10μg/μl leupeptin, 0.1mmol/L PMSF). Aliquots of cell
lysates were boiled in Laemmli buﬀer before running on
SDS-PAGE. Immunoblotting was performed by running
samples on SDS-PAGE with subsequent electrotransfer onto
nitrocellulose membranes (Amersham Pharmacia Biotech,
Amersham, England), blocking with 5% skim milk in
TBS buﬀer with 0.1% Tween 20 for 1h, and incubat-
ing with primary antibody anti-Rac1 was from Upstate
(LakePlacid,NY,USA),anti-phospho-MLC2,anti-phospho-
AKT, and anti-GAPDH were from Cell Signaling (Beverly,
MA, USA), anti-α-tubulin was from Sigma and 1:2000
dilution of the secondary antibody (antigoat, antirabbit,
or antimouse horseradish peroxidase (DAKO, Glostrup,
Denmark)). Development was done by using enhanced
chemiluminescence reagents (Pearce, Rockford, IL, USA)
according to the manufacturer’s speciﬁcations.
2.4. Phosphatidylinositol Kinase Assay. After isolation,
human T cells were incubated for 16 hours in RPMI medium
without serum. Cells pretreated for 15min with or without
ivabradine were stimulated with 100ng/mL SDF-1. Standard
PI 3-kinase activity assays were performed [12] using goat
antihuman p85 (Santa Cruz) antibodies.
2.5. GTPase Activity Assays. For detection of GTP-bound
Rac1, isolated CD4-positive lymphocytes were treated at
37◦C with 100ng/mL SDF-1 in presence or absence of
ivabradine. Cells were lysed for Rac1-GTP pulldown experi-
ments in 500μlR a c 1 - R I P Ab u ﬀer (50mmol/L Tris/HCl, pH
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Figure 4: Ivabradine reduces actin polymerisation in CD4-positive lymphocytes. (a) Isolated lymphocytes were pretreated with ivabradine
(n = 5) for 15min before stimulation with SDF-1. Actin polymerisation was determined by ﬂow cytometry at times indicated. Lower
panel represents statistical analysis for the four timepoints indicated. Bars represent mean ± SD; n = 5; #P<. 05; ∗P<. 01 compared to
SDF-1-stimulated cells.
X-100, 0.5% (w/v) sodium deoxyholate, 10μg/μl aprotinin,
10μg/μl leupeptin, and 0.1mmol/L PMSF). Cell lysates
were cleared by centrifugation in a benchtop centrifuge
at 15800×gf o r1 5m i n u t e sa t+ 4 ◦C. Lysates were then
incubated with 20–40μg glutathione S-transferase- (GST-
) fusion proteins immobilized to Glutathione Sepharose
4B beads for 45 minutes at +4◦C. The active GTP-bound
form of Rac1 was determined by using a GST-PAK fusion
protein. Beads were washed four times with washing buﬀer
(50mmol/L Tris/HCl, pH 7.2, 150mmol/L NaCl, 10mmol/L
MgCL2, 1% (v/v) Triton X-100, 10μg/μl aprotinin, 10μg/μl
leupeptin, and 0.1mmol/L PMSF). Precipitated proteins
were separated on 12% SDS-polyacrylamide gels, trans-
ferred to membrane, and detected by using appropriate
antibodies.
2.6. ICAM3 Staining. Immunoﬂuorescence staining was
performed as described before [13]. In brief, 1-2 × 106
CD-4 positive lymphocytes were incubated in special 4-well
























































Figure 5: Ivabradine abolishes SDF-1-induced ICAM3 transloca-
tion. CD4-positive lymphocytes were pretreated with ivabradine
(0.01, 0.05, or 0.1μmol/L) before stimulation with SDF-1 for
30min. ICAM3 translocation was assayed using immunoﬂuores-
cence staining. ICAM3 translocation at the uropod of migrating
cells is indicated by the arrow. Lower panel shows statistical analysis
of cells positive for ICAM3 translocation as % of DAPI-positive
cells; bars represent mean ± SD; n = 6; ∗P<. 01 compared to SDF-
1-stimulated cells.
500μl complete medium on coverslips coated with collagen.
Before treatment with SDF-1 (100ng/mL, 30min), cells
were incubated with ivabradine for 15min. Cells were then
ﬁxed with 3.7% (wt/vol) paraformaldehyde in PBS, pH
7.4, at room temperature and rinsed in TBS. Cells were
incubated with a speciﬁc antibody against ICAM3 (mouse
antihuman ICAM3, Caltag, UK) and after washing with
PBS, carboxymethylindocyanine 3-Cy3-coupled (Dianova,
Hamburg, Germany) goat antimouse IgGs were added as
secondary antibodies (dilution 1:1,000) for 45min. After
washing again, slides were stained with DAPI (nuclei stain-
ing). Images were recorded with a ﬂuorescence microscope
(Leica, Wetzlar, Germany), and cells in 5 randomly chosen
ﬁelds were analyzed. ICAM-3 translocation was considered
tobe present whenaclearclustering of ICAM3at the uropod
was visible.
2.7. f-Actin Staining. CD4-positive lymphocytes (2 ×
106 cells/ml) were treated with SDF-1 at 100ng/mL for
times indicated after 15min pretreatment with ivabra-
dine. After stimulation, cells were ﬁxed in 3.7% (wt/vol)
paraformaldehyde in PBS, pH 7.4, and then washed at
room temperature in TBS (50mmol/L Tris-HCl, pH 7.6,
150mmol/L NaCl, 0.1% NaN3). For intracellular staining
of f-actin, cells were permeabilized with 0.1% Triton X-
100 for 10min before application of the ﬁrst antibody. Cell
suspensions were incubated for 30min in PBS with FITC-






















































































Figure 6: Ivabradine reduces SDF-1-induced transendothelial
migration of CD4-positive lymphocytes. Human CD4-positive
cells were pretreated with ivabradine for 15 minutes at 0.05 or
0.1μmol/L before migration experiments using SDF-1 (100ng/mL)
were performed in a transendothelial migration assay. Data are
expressed as fold induction compared to SDF-1-stimulated cells.
Bars represent mean ± SD (n = 6); P<. 01 compared to
chemokine-stimulated cells.
analysis was performed in an FACScan cytoﬂuorometer
(Becton Dickinson, Heidelberg, Germany), and induction of
f-actin was measured.
2.8. Transendothelial Migration Assay. Migration of human
CD4-positive lymphocytes across human endothelial cell
monolayers was performed as previously described [14].
Brieﬂy, human endothelial cells were cultured on gelatin-
coatedtranswellﬁlters.CD4-positivelymphocytes(0.5 ×105
cells per well), pretreated for 30 minutes with and without
ivabradine (0.05 or 0.1μmol/L), were added to the upper
chamber of transwells inserts containing 1500μL HBSS.
100ng/mL SDF-1 was placed in the bottom chamber to
initiate transmigration. After 1-hour migration, cells that
had transmigrated to the lower chamber were harvested and
counted by ﬂow cytometry.
2.9. Statistical Analysis. Results of the experimental studies
a r er e p o r t e da sm e a n± standard deviation (SD). Diﬀerences
were analyzed by 1-way ANOVA followed by the appropriate
post-hoc test. A P-value <. 05 was regarded as signiﬁcant.
3. Results
3.1. Ivabradine Reduces SDF-1-Induced CD4-Positive Lym-
phocyte Migration. To examine the eﬀect of ivabradine on
CD4-positive lymphocyte migration, cells were stimulated
with SDF-1 in the absence or presence of ivabradine, and
lymphocyte migration was assessed in a modiﬁed Boyden
chamber. SDF-1 treatment signiﬁcantly induced cell migra-
tion by 2.0 ± 0.1-fold (P<. 01; n = 7), and 15min
pretreatment of cells with ivabradine reduced this eﬀect in
a concentration-dependent manner to a maximal 1.2 ± 0.1-
fold induction at 0.1μmol/L ivabradine (P<. 01 compared
with SDF-1-treated cells; n = 7) (Figure 1(a)).6 Mediators of Inﬂammation
3.2. Ivabradine Reduces RANTES-Induced CD4-Positive Lym-
phocyte Migration. Next, we examined the eﬀect of ivabra-
dine on RANTES-induced lymphocyte migration. Pre-
treatment with ivabradine for 15min reduces RANTES-
induced migration in a concentration-dependent manner to
a maximal 1.1 ± 0.2-fold induction at 0.1μmol ivabradine
(∗P<. 01 compared with RANTES-treated cells; n =
7) (Figure 1(b)). These results suggest that the eﬀect of
ivabradine on lymphocyte migration is independent of the
stimulus employed.
Moreover, ivabradine did not aﬀect cell viability and
had no eﬀect on the expression of the chemokine receptor
CXCR4 as assessed by ﬂow cytometry (data not shown).
3.3. Ivabradine Limits PI-3 Kinase Activity and Phosphory-
lation of AKT in CD4-Positive Lymphocytes. Activation of
PI-3 kinase is a critical step in chemokine-induced T-cell
migration downstream of the respective chemokine receptor
[15]. Therefore, we examined the eﬀect of ivabradine on PI-
3 kinase activity. As demonstrated in Figure 2(a),i v a b r a -
dine limited SDF-1-induced PI-3 kinase activity, suggesting
that ivabradine modulates a very upstream step in the
chemokine-activated signaling cascade.
Downstream of PI-3 kinase phosphorylation of AKT
playsanimportantroleinleucocytemigration[16,17].SDF-
1 treatment signiﬁcantly induced phosphorylation of AKT,
and pretreatment with ivabradine reduced this eﬀect in a
concentration-dependentmannertoamaximal0.2±0.1-fold
induction at 0.1μmol ivabradine (∗P<. 01 compared with
SDF-1-treated cells; n = 3) (Figure 2(b)).
3.4. Ivabradine Inhibits Activation of Rac1 and Phosphory-
lation of MLC. Downstream of PI3K small Rho GTPases
are important signaling molecules involved in leukocyte
migration [18–20]. Therefore, we assessed the eﬀect of
ivabradine on Rac1 activity by performing aﬃnity pre-
cipitation experiments with GST-PAK to which only the
active GTP-bound form of Rac1 can bind. Stimulation with
ivabradine diminished SDF-1-induced Rac1 activity in a
concentration-dependent manner with a maximal eﬀect at
0.1μmol/L (∗P<. 01 compared with SDF-1-treated cells;
n = 5) (Figure 3(a)).
At the uropod of the cell, phosphorylation of MLC is
of critical importance for actin-myosin contractility [21].
Pretreatment of CD4-positive lymphocytes with ivabradine
signiﬁcantly reduced SDF-1-induced phosphorylation of
MLC in a concentration-dependent manner to a maximal
0.5 ± 0.1-fold induction at 0.1μmol/L ivabradine (∗P<. 01
compared with SDF-1-treated cells; n = 5) (Figure 3(b)).
3.5. Ivabradine Reduces f-Actin Formation in CD4-Positive
Lymphocytes. Downstream of Rac1, f-actin formation is a
crucial mechanism in cell polarisation during migration [22,
23]. Ivabradine signiﬁcantly reduced SDF-1-induced f-actin
f o r m a t i o na sd e m o n s t r a t e db yﬂ o wc y t o m e t r y( F i g u r e4).
3.6. Ivabradine Inhibits ICAM3 Translocation in CD4-Positive
Lymphocytes. Next, we examined the eﬀect of ivabradine on
ICAM3 translocation at the uropod of migrating lympho-
cytes, a critical step in cell movement [24]. As shown in
Figure 5, ivabradine signiﬁcantly diminished SDF-1-induced
ICAM3 translocation (Figure 5) with a maximal reduction at
0.1μmol/L.
3.7. Ivabradine Reduces SDF-1-Induced Transendothelial
Migration of CD4-Positive Lymphocytes. To facilitate the
inhibitory eﬀect of Ivabradine on SDF-1-induced migra-
tion of CD4-positive lymphocytes, we examined the eﬀect
of ivabradine on T cells in a transendothelial migra-
tion assay. Pretreatment with ivabradine in a concentra-
tion of 0.05μmol/L or 0.1μmol/L reduces SDF-1-induced
transendothelial migration of CD4-positive lymphocytes
(∗P<. 01, compared with SDF-1-stimulated cells, n = 6,
Figure 6).
4. Discussion
The present study demonstrates that ivabradine inhibits
chemokine-induced migration of CD4-positive lymphocytes
by reducing PI-3 kinase activity, phosphorylation of AKT,
and activation of Rac-1 with subsequent inhibition of MLC-
phosphorylation, f-actin formation, and ICAM3 transloca-
tion.
Ivabradine exerts antianginal and anti-ischemic eﬀects
in patients with stable coronary artery disease. Clinical
trials revealed improved exercise tolerance, increased time
to exercise-induced ischemia, and reduced frequency of
ambient angina attacks after I(f)-channel inhibition [25,
26]. Ivabradine given orally to mice reduces their heart
rateswithoutinﬂuencingleftventricularcontractilefunction
and therefore is used as a tool to study the eﬀects of
heart rate reduction in the vasculature. Ivabradine decreases
markers of vascular oxidative stress, shown by reduced
vascular NADPH oxides activity and decreased markers
of lipid peroxidation. Furthermore, endothelial function
was improved and atherosclerotic plaque formation was
reduced in the ivabradine-treated group [11]. The content
of inﬂammatory cells was not analyzed, especially the eﬀect
on chemokine-induced CD4-positive cell migration.
Chemokine-induced T-cell migration is mediated by
activation of G-protein-coupled receptors leading to an
increase in PI-3 kinase activity [15] with subsequent polar-
ization of cells and formation of a leading edge and the so-
called uropod in the rear [24]. The agonists employed in our
study interfere with this signaling pathway by inhibiting PI-
3 kinase activity and activation of Rac. Interestingly, 15min
pretreatment of CD4-positive cells with ivabradine already
preventedtherapideﬀectofSDF-1onPI3-kinaseactivation,
raising the question of a nontranscriptional eﬀect of these
agents in this context. This rapid eﬀect described here was
already seen for other nuclear receptors, like the PPARα and
PPARγ.Previousstudiesfromourowngroupshowedsimilar
results with PPARγ-activating substances [13]. Downstream
of PI 3-kinase and Rac1, ivabradine leads to a reduction in
f-actin formation and ICAM3 translocation at the uropod
of the cell, thus counterbalancing critical steps in cell
movement [22–24]. In addition, the eﬀect of ivabradineMediators of Inﬂammation 7
on cell migration does not depend on the chemotactic
stimulus, since ivabradine diminished both SDF-1- as well
as RANTES-induced lymphocyte migration. Further studies
should show if this eﬀect of ivabradine in vitro could be also
observed in vivo and how this rapid response of ivabradine
on chemokine-induced migration works.
The importance of chemokine-induced migration and
the chemokine receptor expression was shown in a mouse
model with a genetic deletion of CCR5. In these ApoE−/−
mice, the deletion of CCR5 protects from diet-induced
atherosclerosis, associated with a more stable plaque phe-
notype, reduced mononuclear cell inﬁltration, Th1-type
immune responses, and increased interleukin-10 expression
[27]. Furthermore, blockade of MIF (macrophage migration
inhibitory factor) but not of canonical ligands of CXCR2
or CXCR4 in mice with advanced atherosclerosis led to
plaque regression and reduced monocyte and T-cell content
in plaques [28].
The inhibition of lymphocyte migration shown here may
inﬂuence atherogenesis at a critical step. CD4-positive cells,
once recruited into the subendothelial space by chemokines
like SDF-1 or RANTES, diﬀerentiate to TH1-cells, thus
releasing proinﬂammatory cytokines which then promote
inﬂammatory activation of other cells in the vessel wall [1,
2]. Therefore, modulating the migration of T-lymphocytes
into the vasculature may target the inﬂammatory process in
atherogenesisatanodalpointandassuchmodulateacritical
step in atherosclerotic lesion development.
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